The Montenegrin government is assessing the potential for local production of specific medicines through the state-owned pharmaceutical distributor Montefarm. This initiative aims to mitigate supply risks but necessitates significant investments in manufacturing standards, quality assurance, and regulatory frameworks.
On September 2, discussions regarding pharmaceutical production took place between Montenegrin officials and representatives from Türkiye’s health ministry, as well as the international healthcare organization USHAŞ. Foreign Minister Ervin Ibrahimović indicated that Montefarm intends to begin producing certain medicines and encouraged Turkish firms to explore opportunities for cooperation and investment. However, details such as investment amounts, specific products, or timelines for production have yet to be disclosed.
This proposal marks a noteworthy expansion of Montefarm’s conventional responsibilities. The institution currently procures and distributes medications and medical supplies to Montenegro’s public health system while managing 55 pharmacies nationwide. Since 2021, it has also operated a Galenic Laboratory Sector focused on preparing documentation and ensuring compliance with quality standards necessary for the production of galenic medicines.
The existing laboratory project positions Montenegro to initiate small-scale pharmaceutical preparations more feasibly than establishing a full-scale drug manufacturing facility. Galenic production involves creating medicines in larger batches within authorized pharmacy or healthcare settings using established formulations, which may enable the country to produce selected medicines for public institutions without directly competing with larger European or Asian generic drug manufacturers.
However, the economic viability of such an initiative could be challenged by the complexities associated with manufacturing. With a population of just over 600,000, domestic demand for individual medicines remains limited. Pharmaceutical manufacturing relies heavily on high utilization rates due to substantial fixed costs associated with manufacturing lines, laboratories, quality systems, and regulatory personnel.
A production facility dedicated solely to serving Montenegro would need to concentrate on products where there is a clear justification for local manufacturing due to security of supply or public health needs. Competing in the commodity generic medicines sector at an international scale would prove difficult unless the facility could also tap into export markets.
The regulatory landscape presents additional challenges. Montenegro’s framework for pharmaceuticals mandates rigorous standards for industrial manufacturing to ensure quality, safety, and efficacy. The national medicines agency, CInMED, oversees manufacturer registrations and updated its procedures for manufacturing authorizations and Good Manufacturing Practice (GMP) certification in 2026. Expanding beyond limited galenic production will require comprehensive infrastructure beyond mere production equipment.
Manufacturers must establish controlled environments, hire qualified personnel, validate manufacturing processes, maintain analytical laboratories, document quality systems, and implement batch release procedures along with mechanisms to address deviations and product complaints. Additionally, raw material suppliers must also be under stringent control.
The requirements increase further for sterile products due to critical contamination control measures. Therefore, it is likely that Montenegro’s initial manufacturing efforts will focus on simpler products rather than complex biologics or advanced sterile medications. Türkiye’s involvement could be beneficial given its extensive pharmaceutical manufacturing capabilities.
A partnership with a Turkish firm might provide essential resources such as equipment, production expertise, validated formulations, or training while Montefarm offers insights into local market dynamics and access to Montenegro’s public healthcare supply chain. However, discussions remain preliminary as no Turkish company has committed to investing thus far.
The primary rationale for pursuing local production seems centered around ensuring supply security rather than merely substituting imports. Smaller pharmaceutical markets can face vulnerabilities when larger countries are prioritized during shortages or when low-volume products are deemed commercially unviable by manufacturers. While establishing a domestic facility cannot fully eliminate these risks—given that active pharmaceutical ingredients still need to be imported—it may allow Montenegro greater control over specific products that are frequently challenging to procure.
Montefarm’s established role as a supplier to pharmacies, health centers, hospitals, and other public institutions could provide an advantage by creating predictable demand that makes certain production lines financially viable compared to commercial operations reliant on retail sales.
This structure does raise governance considerations; a state entity involved in both procuring and producing medicines would require clear guidelines to separate production economics from purchasing decisions. Public tenders would need to ensure competition while demonstrating that domestically produced medicines meet appropriate quality standards and offer value.
Otherwise, initiatives aimed at enhancing supply security could inadvertently lead to costly protected manufacturing practices. A more promising opportunity might lie in developing a pharmaceutical services ecosystem around a modest production base.
Montenegro would need professionals specializing in various fields including pharmacy production, analytical chemistry, microbiology, quality assurance, validation engineering, and regulatory affairs. Independent laboratories could also play a role by providing testing services for raw materials and finished products.
Engineering firms might contribute controlled environments and monitoring systems while software companies could develop inventory control and quality management solutions. These functions could remain valuable regardless of whether Montenegro ultimately produces numerous medicines or just a limited strategic selection.
This initiative could enhance the overall resilience of Montenegro’s healthcare system. Establishing pharmaceutical production capabilities would provide expertise useful during shortages or disruptions in regional supply chains—a concern highlighted during the COVID-19 pandemic when many small European nations recognized their reliance on distant manufacturers.
Montenegro faces the challenge of not overextending its ambitions by attempting comprehensive domestic manufacturing. Its size suggests that selective production would be more practical. The strongest business case likely involves producing medicines that address specific supply challenges where technology is manageable and public-sector demand can support fixed costs effectively.
The planned Galenic Laboratory serves as a logical starting point for testing these concepts. Should Montefarm succeed in establishing compliant production processes that demonstrate stable quality at competitive costs compared to imports, it may open avenues for expanding into additional product categories over time.
If economic feasibility at this foundational level proves elusive, justifying a larger-scale pharmaceutical project would become increasingly difficult.
The recent discussions with Turkish representatives do not yet signify the establishment of a Montenegrin pharmaceutical industry but indicate a potential strategic shift towards self-manufacturing within specific segments of the supply chain traditionally dominated by imports.
